SetPoint Medical’s Neuroimmune Modulation Platform Obtains the US FDA’s Breakthrough Device Designation to Treat Multiple Sclerosis
Shots:
- SetPoint Medical’s neuroimmune modulation platform has been granted with the US FDA’s Breakthrough Device Designation for treating relapsing-remitting multiple sclerosis (RRMS). The device also received the US FDA's BDD in 2020 to treat rheumatoid arthritis (RA)
- The company is also investigating its platform technology under the (RESET-RA) clinical program for the treatment of moderate-to-severe RA adults
- The neurostimulation device works by placing it surgically on the vagus nerve. It stimulates the vagus nerve (once daily) to deliver therapy and activate the inflammatory reflex for a systemic immune-restorative effect
Ref: SetPoint Medical | Image: SetPoint Medical
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
